# About Assent Peptides — An Independent Metabolic-Research Digest

> About Assent Peptides: an independent literature digest on two incretin-class research peptides — retatrutide and tirzepatide. How it is compiled, and what it is not.

An independent, citation-anchored digest of the incretin-peptide literature. Not a vendor. Not a clinic. Not medical advice.

## What Assent Peptides is

Assent Peptides is an independent editorial reference desk covering the published research on two incretin-class peptides studied for metabolic regulation and weight management: retatrutide and tirzepatide. The site exists to make a fast-moving, technically dense, and frequently overclaimed literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, at what doses, and how far that evidence reaches.

The organizing frame is the incretin trajectory: tirzepatide is the approved dual agonist against which retatrutide's triple-agonist Phase 3 data will ultimately be measured. Reading them side by side — mechanism, evidence depth, regulatory status, safety signals — gives context that neither compound provides alone. Each has its own page; a comparison page places them side by side; and a single references list aggregates every source.

## How it is compiled

Three principles govern what appears here.

*First, everything is anchored to the peer-reviewed literature.* Every research claim carries a numbered citation — primarily PubMed-indexed journal articles, Phase 1/2/3 clinical trial publications, and systematic reviews — collected on the [references page](/references). Where a finding comes from a Phase 2 trial rather than an approved indication, that distinction is stated explicitly.

*Second, the evidence is reported at its true strength.* Trial results are stated in the populations and durations in which they were studied — never extrapolated to general recommendations or adjusted into personal use guidance. Regulatory status, WADA status, and the limits of available data are stated plainly. For an investigational compound, "investigational" appears wherever context requires it, not once in a disclaimer and never again.

*Third, compounds are not compared beyond what controlled data support.* Retatrutide and tirzepatide trials differ in populations, durations, and enrolled doses; apparent numeric differences are not treated as head-to-head evidence where no such trial exists.

## What it is not

Assent Peptides is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any compound, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person.

The peptides discussed here are prescription medicines or investigational compounds. Neither is approved for over-the-counter or unmonitored use. Readers who have a condition addressed in the underlying research should consult a licensed clinician in their jurisdiction. The value this desk offers is a calm, accurate account of the published literature — not more, and not less.

---

Literature summaries from peer-reviewed trials. No products. No doses. No medical guidance.